| Title |
Analysis of LINE-1 DNA methylation in colorectal cancer, precancerous lesions, and adjacent normal mucosa |
| Authors |
Kildušienė, Inga ; Rynkevičienė, Rytė ; Kačėnienė, Augustė ; Miknaitė, Rima ; Sužiedėlis, Kęstutis ; Smailytė, Giedrė |
| DOI |
10.3390/medicina61071243 |
| Full Text |
|
| Is Part of |
Medicina (Lithuania).. Basel : MDPI. 2025, vol. 61, iss. 7, art. no. 1243, p. [1-7].. ISSN 1010-660X. eISSN 1648-9144 |
| Keywords [eng] |
colorectal cancer ; LINE-1 ; methylation |
| Abstract [eng] |
Background and Objectives: Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality worldwide. Genetic and epigenetic changes, especially DNA methylation alterations, are key in CRC development. LINE-1 hypomethylation marks global DNA methylation loss and genomic instability, making it a potential early CRC biomarker. This study investigates the methylation status of LINE-1 in colorectal adenocarcinoma, precancerous lesions (tubular and serrated adenomas), and the surrounding normal mucosa, aiming to elucidate its role as an epigenetic marker in early colorectal tumorigenesis. Materials and Methods: Paired lesion and normal tissue samples from 66 patients were analyzed for LINE-1 methylation at three CpG sites using bisulfite pyrosequencing. Results: Adenocarcinomas and tubular adenomas showed significant hypomethylation, especially at loci A and B, while serrated adenomas exhibited no significant differences. Conclusions: LINE-1 hypomethylation is associated with colorectal tumorigenesis, with distinct patterns observed between tubular and serrated adenomas, indicating distinct pathways forming and progressing specific adenomas. These findings support the potential of LINE-1 methylation as an early epigenetic biomarker for CRC risk stratification and highlight the need for further research into its clinical utility. |
| Published |
Basel : MDPI |
| Type |
Journal article |
| Language |
English |
| Publication date |
2025 |
| CC license |
|
